BDX vs RNAZ · P/E 34, rev $21.84B vs $5.1M cap
Becton Dickinson and Company (BDX) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
RNAZ does not have a complete income-statement cache yet.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the BDX and RNAZ stock pages for the full models.
Not investment advice.